|
Video: What is a Stock Split?
|
|
Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. According to our RPRX split history records, Royalty Pharma has had 0 splits. | |
|
Royalty Pharma (RPRX) has 0 splits in our RPRX split history database.
Looking at the RPRX split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Royalty Pharma shares, starting with a $10,000 purchase of RPRX, presented on a split-history-adjusted basis factoring in the complete RPRX split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
06/16/2020 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$44.50 |
|
End price/share: |
$27.82 |
|
Starting shares: |
224.72 |
|
Ending shares: |
242.10 |
|
Dividends reinvested/share: |
$2.75 |
|
Total return: |
-32.65% |
|
Average Annual Total Return: |
-9.75% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,733.77 |
|
Years: |
3.85 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/16/2020 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$44.50 |
|
End price/share: |
$27.82 |
|
Dividends collected/share: |
$2.75 |
|
Total return: |
-31.30% |
|
Average Annual Total Return: |
-9.28% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,869.96 |
|
Years: |
3.85 |
|
|
|
|
|